Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MEG.0000000000002227 | DOI Listing |
Clin Gastroenterol Hepatol
December 2024
Division of Gastroenterology, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. Electronic address:
Background & Aims: Noninvasive tests (NITs) for ruling-out clinical significant portal hypertension (CSPH) and high-risk varices (HRVs) in patients with primary biliary cholangitis (PBC) and compensated advanced chronic liver disease (cACLD) are lacking. We evaluated NITs in these patients and the influence of cholestasis on their performance.
Methods: Consecutive patients from the "Italian PBC registry" and 2 United Kingdom large-volume PBC referral centers with upper endoscopy within 6 months from biochemical evaluation and transient elastography were included.
J Clin Exp Hepatol
August 2024
Department of Radiology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
J Pediatr Gastroenterol Nutr
August 2024
Departments of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Objective: Biliary atresia (BA) is the leading cause of liver cirrhosis and chronic liver insufficiency in children in the world. Gastroesophageal varices bleeding is an ominous complication of cirrhosis in BA patients and is associated with high morbidity and mortality. In this study, we aimed to investigate the utility of noninvasive Baveno VI and Baveno VII criteria for the screening of varices need treatment (VNT) and the need for liver transplantation in BA patients.
View Article and Find Full Text PDFMedicina (Kaunas)
April 2024
Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, 90127 Palermo, Italy.
Clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease indicates an increased risk of decompensation and death. While invasive methods like hepatic venous-portal gradient measurement is considered the gold standard, non-invasive tests (NITs) have emerged as valuable tools for diagnosing and monitoring CSPH. This review comprehensively explores non-invasive diagnostic modalities for portal hypertension, focusing on NITs in the setting of hepatitis B and hepatitis C virus-related cirrhosis.
View Article and Find Full Text PDFJHEP Rep
February 2024
Liver Unit, Digestive Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus. Universitat Autònoma de Barcelona, Barcelona, Spain.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!